NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model

Biochemical and Biophysical Research Communications

Volumn 419, Issue 3, 2012, Pages 523-528

  Chattopadhyay, Mitali ^a   Kodela, Ravinder ^a   Olson, Kenneth R ^b   Kashfi, Khosrow ^a  

^a CITY UNIVERSITY OF NEW YORK MEDICAL SCHOOL   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti colon cancer; Anti inflammatory; Aspirin; Chemoprevention; Colon cancer; Hydrogen sulfide; Nitric oxide; NOSH aspirin

Indexed keywords

4 (3 THIOXO 3H 1, 2 DITHIOL 5 YL) PHENYL 2 [(4 (NITROOXY)BUTANOYL] BENZOATE; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; HYDROGEN SULFIDE; INDOMETACIN; NBS 1120; NITRIC OXIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; IC 50; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASPIRIN; CELL CYCLE; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLOOXYGENASE INHIBITORS; DISULFIDES; HT29 CELLS; HUMANS; HYDROGEN SULFIDE; MICE; MICE, NUDE; NITRATES; NITRIC OXIDE; NITRIC OXIDE DONORS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; OVIS;

EID: 84858289256     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.051     Document Type: Article

References (29)

1. Thun M.J., Henley S.J., Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer Inst. 2002, 94:252-266.
2. Bjorkman D.J. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am. J. Med. 1999, 107:3S-8S.
3. discussion 8S-10S.
4. del Soldato P., Sorrentino R., Pinto A. NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol. Sci. 1999, 20:319-323.
5. Wallace J.L., Del Soldato P. The therapeutic potential of NO-NSAIDs. Fundam. Clin. Pharmacol. 2003, 17:11-20.
6. Wallace J.L., Reuter B., Cicala C., McKnight W., Grisham M., Cirino G. A diclofenac derivative without ulcerogenic properties. Eur. J. Pharmacol. 1994, 257:249-255.
7. Fiorucci S., Santucci L., Gresele P., Faccino R.M., Del Soldato P., Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003, 124:600-607.
8. Fabbri F., Brigliadori G., Ulivi P., Tesei A., Vannini I., Rosetti M., Bravaccini S., Amadori D., Bolla M., Zoli W. Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells. Apoptosis 2005, 10:1095-1103.
9. Kashfi K. Anti-inflammatory agents as cancer therapeutics. Adv. Pharmacol. 2009, 57:31-89.
10. Khan N.I., Cisterne A., Baraz R., Bradstock K.F., Bendall L.J. Para-NO-aspirin inhibits NF-kappaB and induces apoptosis in B-cell progenitor acute lymphoblastic leukemia. Exp. Hematol. 2012, 40:207-215.
11. Fiorucci S., Antonelli E., Distrutti E., Rizzo G., Mencarelli A., Orlandi S., Zanardo R., Renga B., Di Sante M., Morelli A., Cirino G., Wallace J.L. Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology 2005, 129:1210-1224.
12. Distrutti E., Sediari L., Mencarelli A., Renga B., Orlandi S., Antonelli E., Roviezzo F., Morelli A., Cirino G., Wallace J.L., Fiorucci S. Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J. Pharmacol. Exp. Ther. 2006, 316:325-335.
13. Fiorucci S., Orlandi S., Mencarelli A., Caliendo G., Santagada V., Distrutti E., Santucci L., Cirino G., Wallace J.L. Enhanced activity of a hydrogen sulphide-releasing derivative of mesalamine (ATB-429) in a mouse model of colitis. Br. J. Pharmacol. 2007, 150:996-1002.
14. Wallace J.L., Caliendo G., Santagada V., Cirino G., Fiorucci S. Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat. Gastroenterology 2007, 132:261-271.
15. Li L., Rossoni G., Sparatore A., Lee L.C., Del Soldato P., Moore P.K. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. Free Radic. Biol. Med. 2007, 42:706-719.
16. Wallace J.L., Caliendo G., Santagada V., Cirino G. Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br. J. Pharmacol. 2010, 159:1236-1246.
17. Chattopadhyay M., Kodela R., Nath N., Dastagirzada Y.M., Velázquez C.A., Boring D., Kashfi K. Hydrogen sulfide-releasing NSAIDs inhibit the growth of cultured human cancer cells: a general property and evidence of a tissue type-independent effect. Biochem. Pharmacol. 2012, 83:715-722.
18. Chattopadhyay M., Kodela R., Nath N., Barsegian A., Boring D., Kashfi K. Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. Biochem. Pharmacol. 2012, 83:723-733.
19. Kodela R., Chattopadhyay M., Kashfi K. NOSH-aspirin: a novel nitric oxide-hydrogen sulfide-releasing hybrid: a new class of anti-inflammatory pharmaceuticals. ACS Med. Chem. Letts. 2012, 56. 10.1021/ml300002m.
20. Penning T.D., Talley J.J., Bertenshaw S.R., Carter J.S., Collins P.W., Docter S., Graneto M.J., Lee L.F., Malecha J.W., Miyashiro J.M., Rogers R.S., Rogier D.J., Yu S.S., AndersonGd, Burton E.G., Cogburn J.N., Gregory S.A., Koboldt C.M., Perkins W.E., Seibert K., Veenhuizen A.W., Zhang Y.Y., Isakson P.C. Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide SC-58635, celecoxib. J. Med. Chem. 1997, 40:1347-1365.
21. Kashfi K., Borgo S., Williams J.L., Chen J., Gao J., Glekas A., Benedini F., Del Soldato P., Rigas B. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J. Pharmacol. Exp. Ther. 2005, 312:978-988.
22. Li L., Bhatia M., Zhu Y.Z., Zhu Y.C., Ramnath R.D., Wang Z.J., Anuar F.B., Whiteman M., Salto-Tellez M., Moore P.K. Hydrogen sulfide is a novel mediator of lipopolysaccharide-induced inflammation in the mouse. Faseb. J. 2005, 19:1196-1198.
23. Huang S., Chua J.H., Yew W.S., Sivaraman J., Moore P.K., Tan C.H., Deng L.W. Site-directed mutagenesis on human cystathionine-gamma-lyase reveals insights into the modulation of H2S production. J. Mol. Biol. 2010, 396:708-718.
24. Olson K.R. Is hydrogen sulfide a circulating " gasotransmitter" in vertebrate blood?. Biochim. Biophys. Acta 2009, 1787:856-863.
25. Kulmacz R.J., Lands W.E. Requirements for hydroperoxide by the cyclooxygenase and peroxidase activities of prostaglandin H synthase. Prostaglandins 1983, 25:531-540.
26. Roninson I.B., Broude E.V., Chang B.D. If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist. Updat. 2001, 4:303-313.
27. Deleon E.R., Stoy G.F., Olson K.R. Passive loss of hydrogen sulfide in biological experiments. Anal. Biochem. 2012, 421:203-207.
28. Meade E.A., Smith W.L., DeWitt D.L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 1993, 268:6610-6614.
29. Riendeau D., Charleson S., Cromlish W., Mancini J.A., Wong E., Guay J. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays. Can. J. Physiol. Pharmacol. 1997, 75:1088-1095.